Reduced BAP1 expression has been linked to poor prognosis and adverse tumor features in renal carcinoma [10–12], colorectal cancer [34], gastric adenocarcinoma [35], non-small cell lung cancer [8, 9], gall bladder cancer [13] and uveal melanoma [16–18, 36]. Here, BAP1 is linked to colorectal cancer.